CSF2 and breast cancer: In a subsequent study, the induction of antitumor immunity was studied in patients with solid tumors (16 with breast cancer) by comparing a single intratumoral injection of Ad5/3-D24-GMCSF (CGTG-102) with the administration of three subsequent doses 3 to 4 weeks apart (44).